6:01 AM ET
8-K
Shareholder Meeting
Lakewood-Amedex Biotherapeutics Shareholder Meeting
Lakewood-Amedex Biotherapeutics held its 2026 Annual Meeting where stockholders elected four directors and approved several key proposals. These included increasing authorized common shares from 12.5 million to 100 million, authorizing a potential reverse stock split at a ratio of up to 1-for-20, and increasing shares issuable under the 2020 Equity Incentive Plan to 400,000.